Weaning Approaches for Vasopressin in Sepsis
Recruiting
Phase 3
Interventional Study
Septic Shock
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 82 (estimated)
- Sponsor
- Hospital Nossa Senhora da Conceicao · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this study, we aim to evaluate the incidence of hypotension during vasopressin weaning by comparing two methods - titrated reduction versus abrupt withdrawal - through the conduct of a randomized clinical trial.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age over 18 years
* Admitted to the Intensive Care Unit
* Patients with vasopressor dependent sepsis
* Receiving combined norepinephrine and vasopressin therapy
Exclusion Criteria:
* Withdrawal/reduction of vasopressin related to a plan of treatment limitation or palliative …
Contacts